SRSTOCK RADAR

Today

July 25, 2026

Today's Alerts

11Last 24H

Dilution Risk

2Last 7D

Listing Risk

37Last 30D

Earnings

8Last 7D

Insider / Ownership

3Last 14D

Dividends

1Last 30D

FDA / Clinical

13Last 30D
HEN/A+0.00%
Legal Risk
Hawaiian Electric Settles Maui Wildfire Tort Litigation for $1.99 Billion

Hawaiian Electric reached a definitive $1.99 billion settlement for Maui wildfire tort claims, reducing significant legal and financial uncertainty.

bullishImpact 80
EQIXN/A+0.00%
Legal Risk
Equinix Under Investigation Following Short Seller Report and Subpoena

Equinix is facing an independent investigation by its Audit Committee and a federal subpoena related to a short seller report.

bearishImpact 75
TN/A+0.00%
Legal Risk
AT&T Discloses Material Cybersecurity Incident Affecting Customer Call Logs

AT&T disclosed a material cybersecurity incident involving the unauthorized access of customer call and text logs from a third-party cloud platform.

bearishImpact 65
WULFN/A+0.00%
Operating Update
TeraWulf Announces March 2024 Production and Operations Update

TeraWulf reported increased bitcoin production and hash rate for March, alongside efficiency gains and plans to expand capacity to 10 EH/s by mid-2024.

bullishImpact 65
GAUZN/A+0.00%
IPO / Listing
Gauzy Ltd. Closes $75 Million Initial Public Offering

Gauzy Ltd. has completed its initial public offering, raising $75 million in gross proceeds.

neutralImpact 70
INFQN/A+0.00%
IPO / Listing
Churchill Capital Corp X Completes $414 Million SPAC IPO

Churchill Capital Corp X has completed its initial public offering, raising $414 million for its SPAC operations.

neutralImpact 60
OTLKN/A+0.00%
FDA / Clinical
FDA Grants Appeal for ONS-5010/LYTENAVA™ BLA

Outlook Therapeutics' appeal for its nAMD treatment, ONS-5010/LYTENAVA™, has been granted by the FDA, paving the way for a BLA resubmission.

bullishImpact 80
ARVNN/A+0.00%
FDA / Clinical
FDA Approves VEPPANU for Advanced Breast Cancer

Arvinas received FDA approval for VEPPANU, its lead PROTAC drug for advanced breast cancer, triggering a $50 million milestone payment.

bullishImpact 88
CAPRN/A+0.00%
FDA / Clinical
FDA Advisory Committee Meeting Scheduled for Deramiocel BLA Review

Capricor Therapeutics announced an FDA Advisory Committee meeting for its Duchenne muscular dystrophy therapy, Deramiocel, ahead of an August PDUFA date.

volatileImpact 75
NTLAN/A+0.00%
Dilution Risk
Intellia Therapeutics Expands ATM Offering to Over $1 Billion and Announces FDA Lift of Clinical Hold

Intellia Therapeutics increased its at-the-market offering program by $285.3 million to a total of $1.035 billion, alongside news of an FDA clinical hold lift.

volatileImpact 70
RAREN/A+0.00%
FDA / Clinical
FDA Accepts Ultragenyx's Gene Therapy BLA for Priority Review

Ultragenyx's gene therapy for GSDIa received FDA Priority Review, setting an August 2026 action date.

bullishImpact 75
RAREN/A+0.00%
FDA / Clinical
FDA Clears IND for Ultragenyx's UX016 for GNE Myopathy

Ultragenyx received FDA clearance for its IND application for UX016, enabling a Phase 1/2 study for GNE myopathy.

bullishImpact 75
RANGN/A+0.00%
Leadership / Governance
Range Capital Acquisition Corp. Changes Independent Auditor

Range Capital Acquisition Corp. appointed CBIZ CPAs P.C. as its new auditor after Marcum LLP resigned, with the prior audit report noting going concern issues.

volatileImpact 55
DCON/A+0.00%
Financial Risk
Ducommun Inc. announces non-reliance on past financial statements and plans restatement

Ducommun Inc. declared its past financial statements unreliable due to an accounting error, requiring a restatement and revealing a material weakness in internal controls.

bearishImpact 78
STELN/A+0.00%
Earnings
Stellar Bancorp Reports Q3 2025 Financial Results

Stellar Bancorp reported slightly lower Q3 2025 earnings but showed improved net interest margin and a stronger capital position.

neutralImpact 60
YOUN/A+0.00%
Earnings
Clear Secure Reports Strong Q4 and Full-Year 2025 Results with Increased Dividends and Share Buyback

Clear Secure reported strong Q4 and full-year 2025 financial results, with significant growth in revenue and Adjusted EBITDA, alongside increased dividends and an expanded share repurchase program.

bullishImpact 78
SCSN/A+0.00%
Earnings
Steelcase Reports Strong Q1 FY26 Results and Positive Q2 Outlook

Steelcase reported better-than-expected first-quarter results with strong revenue growth and improved margins, alongside an optimistic second-quarter outlook.

bullishImpact 70
HUTN/A+0.00%
Financial Risk
Hut 8 Corp. Secures $200M Bitcoin-Backed Revolving Credit Facility

Hut 8 Corp. secured a new $200 million revolving credit facility collateralized by Bitcoin, introducing both liquidity and significant market-driven risk.

volatileImpact 70
KRN/A+0.00%
Financial Risk
Kroger to Redeem $4.7 Billion in Senior Notes Following Albertsons Merger Termination

Kroger will redeem $4.7 billion in senior notes on December 18, 2024, at 101% of principal, triggered by the termination of its merger agreement with Albertsons.

bearishImpact 78
BGN/A+0.00%
Financial Risk
Bunge Global SA Subsidiary Secures $2 Billion Term Loan for Viterra Acquisition

Bunge Global SA's subsidiary secured a new $2 billion term loan, guaranteed by the parent, to finance the Viterra acquisition and refinance existing debt.

bearishImpact 70